# Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition

> **NCT03111810** · PHASE2 · COMPLETED · sponsor: **University of Oxford** · enrollment: 32 (actual)

## Conditions studied

- Iatrogenic Cushing's Disease

## Interventions

- **DRUG:** AZD4017 and prednisolone
- **DRUG:** Placebo Oral Tablet and prednisolone

## Key facts

- **NCT ID:** NCT03111810
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-25
- **Primary completion:** 2020-08-01
- **Final completion:** 2020-08-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03111810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03111810, "Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03111810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*